BioCentury | May 8, 2020
Finance

Follow-on market poised for comeback, at least temporarily

Pandemic-driven market volatility has stymied follow-on activity the past two months, but stabilizing markets and big inflows are opening a window of opportunity, at least in the near term. The unfolding consequences of COVID-19 could...
BioCentury | May 25, 2018
Finance

HKEX’s on-demand experts

...highly vulnerable to the complexities of the biotech business model. Fok said protecting these “less sophisticated investors”...
BioCentury | Apr 24, 2018
Financial News

HKEX finalizes biotech chapter listing rules

...from a "sophisticated investor." HKEX declined to give definitions of either, but instead gave examples. Sophisticated investors...
BioCentury | Mar 30, 2018
Finance

Heading for Hong Kong

...the entry of pre-revenue biotechs (see BioCentury, March 16) . “There’s no lack of very sophisticated investors...
BioCentury | Mar 30, 2018
Financial News

BayHelix releases survey results for Hong Kong stock exchange proposals

Results from a BayHelix Group survey show 85% of 117 respondents believe shares purchased by “cornerstone investors” should be included in the book-building process for biotechs looking to list on Hong Kong Exchanges and Clearing...
BioCentury | Mar 26, 2018
Financial News

BayHelix members weigh in on Hong Kong exchange proposals

Results from a BayHelix Group survey show 85% of 117 respondents believe shares purchased by “cornerstone investors” should be included in the book-building process for biotechs looking to list on Hong Kong Exchanges and Clearing...
BioCentury | Mar 16, 2018
Finance

Hong Kong’s new chapter

Introducing a biotech chapter to the Hong Kong stock exchange fills a massive void in the region’s innovation ecosystem, but won’t come without risks. It promises to create a long sought public capital market for...
BioCentury | Dec 22, 2017
Financial News

HKSE proposes to expand listing eligibility for biotechs

Hong Kong Exchanges and Clearing Ltd. (HKEX) said Dec. 15 that it will amend its listing rules to allow pre-revenue biotechs and companies from emerging and innovative sectors with weighted voting rights (WVR) structures to...
BioCentury | Dec 16, 2017
Financial News

HKSE proposes to expand listing eligibility for biotechs

Hong Kong Exchanges and Clearing Ltd. (HKEX) said Friday that it will amend its listing rules to allow pre-revenue biotechs and companies from emerging and innovative sectors with weighted voting rights (WVR) structures to list...
BioCentury | Oct 26, 2015
Financial News

Avita completes private placement

...$7.3 million) Shares: 107.7 million Price: A$0.09 Shares after offering: 532.8 million Investors: Institutional investors; sophisticated investors WIR...
Items per page:
1 - 10 of 26
BioCentury | May 8, 2020
Finance

Follow-on market poised for comeback, at least temporarily

Pandemic-driven market volatility has stymied follow-on activity the past two months, but stabilizing markets and big inflows are opening a window of opportunity, at least in the near term. The unfolding consequences of COVID-19 could...
BioCentury | May 25, 2018
Finance

HKEX’s on-demand experts

...highly vulnerable to the complexities of the biotech business model. Fok said protecting these “less sophisticated investors”...
BioCentury | Apr 24, 2018
Financial News

HKEX finalizes biotech chapter listing rules

...from a "sophisticated investor." HKEX declined to give definitions of either, but instead gave examples. Sophisticated investors...
BioCentury | Mar 30, 2018
Finance

Heading for Hong Kong

...the entry of pre-revenue biotechs (see BioCentury, March 16) . “There’s no lack of very sophisticated investors...
BioCentury | Mar 30, 2018
Financial News

BayHelix releases survey results for Hong Kong stock exchange proposals

Results from a BayHelix Group survey show 85% of 117 respondents believe shares purchased by “cornerstone investors” should be included in the book-building process for biotechs looking to list on Hong Kong Exchanges and Clearing...
BioCentury | Mar 26, 2018
Financial News

BayHelix members weigh in on Hong Kong exchange proposals

Results from a BayHelix Group survey show 85% of 117 respondents believe shares purchased by “cornerstone investors” should be included in the book-building process for biotechs looking to list on Hong Kong Exchanges and Clearing...
BioCentury | Mar 16, 2018
Finance

Hong Kong’s new chapter

Introducing a biotech chapter to the Hong Kong stock exchange fills a massive void in the region’s innovation ecosystem, but won’t come without risks. It promises to create a long sought public capital market for...
BioCentury | Dec 22, 2017
Financial News

HKSE proposes to expand listing eligibility for biotechs

Hong Kong Exchanges and Clearing Ltd. (HKEX) said Dec. 15 that it will amend its listing rules to allow pre-revenue biotechs and companies from emerging and innovative sectors with weighted voting rights (WVR) structures to...
BioCentury | Dec 16, 2017
Financial News

HKSE proposes to expand listing eligibility for biotechs

Hong Kong Exchanges and Clearing Ltd. (HKEX) said Friday that it will amend its listing rules to allow pre-revenue biotechs and companies from emerging and innovative sectors with weighted voting rights (WVR) structures to list...
BioCentury | Oct 26, 2015
Financial News

Avita completes private placement

...$7.3 million) Shares: 107.7 million Price: A$0.09 Shares after offering: 532.8 million Investors: Institutional investors; sophisticated investors WIR...
Items per page:
1 - 10 of 26